{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:01:24Z","timestamp":1791396084855,"version":"4.3.3"},"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2013,8,23]],"date-time":"2013-08-23T00:00:00Z","timestamp":1377216000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0071596","type":"journal-article","created":{"date-parts":[[2013,8,23]],"date-time":"2013-08-23T17:11:07Z","timestamp":1377277867000},"page":"e71596","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":35,"title":["Variable Behavior of iPSCs Derived from CML Patients for Response to TKI and Hematopoietic Differentiation"],"prefix":"10.1371","volume":"8","author":[{"given":"Aur\u00e9lie","family":"Bedel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean- Max","family":"Pasquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9ric","family":"Lippert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Taillepierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Lagarde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Dabernat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Dubus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Charaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Beliveau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"de Verneuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois-Xavier","family":"Mahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Moreau-Gaudry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,8,23]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc3317","article-title":"Pushing the limits of targeted therapy in chronic myeloid leukaemia","volume":"12","author":"T O'Hare","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"BJ Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"FX Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alpha plus cytarabine in newly diagnosed chronic myeloid leukemia. International Randomised Study of Interferon versus STI571 (IRIS) Study Group","volume":"349","author":"TP Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"SM Graham","year":"2002","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"AS Corbin","year":"2011","journal-title":"J Clin Invest"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival","volume":"119","author":"A Hamilton","year":"2012","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","article-title":"Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors","volume":"126","author":"K Takahashi","year":"2006","journal-title":"Cell"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","article-title":"Induction of pluripotent stem cells from adult human fibroblasts by defined factors","volume":"131","author":"K Takahashi","year":"2007","journal-title":"Cell"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1126\/science.1151526","article-title":"Induced pluripotent stem cell lines derived from human somatic cells","volume":"318","author":"J Yu","year":"2007","journal-title":"Science"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.gde.2012.05.005","article-title":"New lessons learned from disease modeling with induced pluripotent stem cells","volume":"22","author":"TT Onder","year":"2012","journal-title":"Curr Opin Genet Dev"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ajhg.2012.05.026","article-title":"Metabolic correction of congenital erythropoietic porphyria with iPSCs free of reprogramming factors","volume":"91","author":"A Bedel","year":"2012","journal-title":"Am J Hum Genet"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood-2010-10-313692","article-title":"Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells","volume":"118","author":"R Gioia","year":"2011","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/leu.2008.364","article-title":"The stem cell factor-c-KIT pathway must be inhibited to enable apoptosis induced by BCR-ABL inhibitors in chronic myelogenous leukemia cells","volume":"23","author":"F Belloc","year":"2009","journal-title":"Leukemia"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/stem.657","article-title":"Brief report: efficient generation of hematopoietic precursors and progenitors from human pluripotent stem cell lines","volume":"29","author":"NB Woods","year":"2011","journal-title":"Stem Cells"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cellsig.2008.09.006","article-title":"BCR-ABL induces opposite phenotypes in murine ES cells according to STAT3 activation levels","volume":"21","author":"P Coppo","year":"2009","journal-title":"Cell Signal"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.molmed.2012.04.001","article-title":"iPSCs from cancer cells: challenges and opportunities","volume":"18","author":"V Ramos-Mejia","year":"2012","journal-title":"Trends Mol Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"9222","DOI":"10.1073\/pnas.1004584107","article-title":"Human embryonic stem cells with biological and epigenetic characteristics similar to those of mouse ESCs","volume":"107","author":"J Hanna","year":"2010","journal-title":"PNAS"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1182\/blood-2009-07-231845","article-title":"Generation of iPSCs from cultured human malignant cells","volume":"115","author":"JE Carette","year":"2010","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1182\/blood-2010-07-298331","article-title":"Efficient generation of transgene-free induced pluripotent stem cells from normal and neoplastic bone marrow and cord blood mononuclear cells","volume":"117","author":"K Hu","year":"2011","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1182\/blood-2011-07-367441","article-title":"Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples","volume":"119","author":"K Kumano","year":"2012","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1172\/JCI67146","article-title":"Defective telomere elongation and hematopoiesis from telomerase-mutant aplastic anemia iPSCs","volume":"123","author":"T Winkler","year":"2013","journal-title":"J Clin Invest"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ccr.2012.03.003","article-title":"Cancer stem cells: impact, heterogeneity, and uncertainty","volume":"21","author":"JA Magee","year":"2012","journal-title":"Cancer Cell"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.3324\/haematol.2012.062844","article-title":"Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials","volume":"97","author":"M Tang","year":"2012","journal-title":"Haematologica"},{"key":"ref25","first-page":"e35824","article-title":"Residual expression of the reprogramming factors prevents differentiation of iPSC generated from human fibroblasts and cord blood CD34+ progenitors. PLoS One","volume":"7","author":"V Ramos-Mej\u00eda","year":"2012"},{"key":"ref26","first-page":"102","article-title":"Overproduction of BCR-ABL induces apoptosis in imatinib mesylate-resistant cell lines. Cancer","volume":"103","author":"V Desplat","year":"2005"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0071596","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T19:21:55Z","timestamp":1540322515000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0071596"}},"subtitle":[],"editor":[{"given":"Connie J.","family":"Eaves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,8,23]]},"references-count":26,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2013,8,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0071596","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,23]]}}}